Fig. 5

Combination therapy comprising adoptive transfer OVA-specific cytotoxic T lymphocytes (OVA-CTLs) and PLGA nanoparticles encapsulated with PF-562271 (PLGA-FAKi) in B16-OVA tumor-bearing C57BL/6 mice. a, b Tumor growth curves (a) and body weights (b) of B16-OVA tumor-bearing C57BL/6 mice (n = 7/group) after intravenous injection of PBS (control), PLGA, PLGA-FAKi, OVA-CTLs, OVA-CTLs plus PLGA, or OVA-CTLs plus PLGA-FAKi. c Quantitative analysis of Ki67-positive cells in the tumors harvested from mice after the indicated treatments (n = 5). d, e Quantified CD4⁺ T cells (CD3⁺CD4⁺), CD8⁺ T cells (CD3⁺CD8⁺), and T-regulatory cells (CD4⁺FoxP3⁺), and quantified M2 macrophages (F4/80⁺CD206⁺) and M2-to-M1 macrophage ratios in the B16-OVA tumors harvested from C57BL/6 mice (n = 5/group) after treatment with PLGA or PLGA-FAKi. Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001